Bristol Myers forecasts steeper drop in 2025 revenue, shares fall
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Bristol-Myers Squibb Co. (BMY) PT Raised to $67 at Goldman Sachs
February 7, 2025 7:48 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $67.00 (from $65.00) while maintaining a Buy rating.
The analyst comments "With delivery of overall solid performance from 4Q24 (top and bottom line beats vs. consensus), while share reactions on the day reflected 2025 guidance coming in modestly below expectations, we see the essential... More
